Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT06461182 Recruiting - Clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma

Ga-68-CXCR4 PET/CT in Indolent B-cell Lymphoma

PentixaFor
Start date: April 29, 2024
Phase: Phase 2
Study type: Interventional

This study explores the efficacy of Ga-68-PentixaFor PET/CT in detecting, assessing treatment response, and monitoring the risk of aggressiveness in indolent B-cell lymphoma. The background introduces CXCR4 and discusses its role in cancer research. Currently, FDG-PET is the primary imaging tool for lymphoma staging, but it lacks diagnostic accuracy for low-grade lymphomas. Ga-68-PentixaFor PET demonstrates promising detection capabilities across various lymphomas, suggesting its potential as a superior imaging modality for low-grade lymphomas.

NCT ID: NCT06458439 Not yet recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Start date: July 2024
Phase: Phase 2
Study type: Interventional

This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.

NCT ID: NCT06454968 Recruiting - Clinical trials for Marginal Zone Lymphoma

Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab and lenalidomide in untreated marginal zone lymphoma. The primary objective was the best complete response rate (CRR).

NCT ID: NCT06454266 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen)

Start date: December 28, 2021
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of first-line treatment of primary central nervous system lymphoma with the combination of orelabrutinib, rituximab and methotrexate (ORM regimen).

NCT ID: NCT06454149 Recruiting - Clinical trials for Gastric MALT Lymphoma

Cohort Study for Gastric MALT Lymphoma

HUG-MALToma
Start date: June 6, 2024
Phase:
Study type: Observational [Patient Registry]

The goal of this observational study is to establish clinical data and tissue repository in patients with gastric MALT lymphoma and controls. Participants will be asked to provide clinical information and various tissues (saliva, gastric mucosa, and feces).

NCT ID: NCT06453044 Not yet recruiting - Clinical trials for Recurrent Grade 2 Follicular Lymphoma

Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma

Start date: August 24, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Giving mosunetuzumab and polatuzumab vedotin may kill more cancer cells in patients with relapsed or refractory grade 1-3a follicular lymphoma.

NCT ID: NCT06449885 Recruiting - Clinical trials for Marginal Zone Lymphoma

A Cohort Study in Newly Diagnosed MZL

Start date: May 30, 2024
Phase:
Study type: Observational

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

NCT ID: NCT06446128 Active, not recruiting - Clinical trials for Non-Hodgkin Lymphoma, B-cell

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Start date: April 1, 2024
Phase: Early Phase 1
Study type: Interventional

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous chimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

NCT ID: NCT06445803 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia, in Relapse

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Start date: May 31, 2024
Phase: Phase 1
Study type: Interventional

This study examines the safety, tolerability and preliminary efficacy of anti-CD19 /CD22 CAR T cells (KQ-2002)manufactured on-site in adults with relapsed or refractory CD19+ B cell acute lymphoblastic leukemia or CD19+ B cell non Hodgkin lymphoma.

NCT ID: NCT06445517 Recruiting - Clinical trials for Advanced Solid Tumors

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Start date: April 25, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma. The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsed/refractory B-cell lymphoma